Page 10 - Read Online
P. 10

Fanella et al. J Transl Genet Genom 2021;5:124-9  https://dx.doi.org/10.20517/jtgg.2021.11  Page 128

               Manuscript revision and critical reappraisal: Ferracuti S
               Study conception, manuscript revision and critical reappraisal: Di Bonaventura C

               Availability of data and materials
               Clinical data and reports supporting the results reported in this article can be found in the patient’s medical
               records.


               Financial support and sponsorship
               None.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               A written informed consent for publication was obtained.

               Copyright
               © The Author(s) 2021.

               REFERENCES
               1.       Daston MM, Scrable H, Nordlund M, Sturbaum AK, Nissen LM, Ratner N. The protein product of the neurofibromatosis type 1 gene
                   is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992;8:415-28.  DOI  PubMed
               2.       Malhotra R, Ratner N. Localization of neurofibromin to keratinocytes and melanocytes in developing rat and human skin. J Invest
                   Dermatol 1994;102:812-8.  DOI  PubMed
               3.       Martin GA, Viskoohil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.
                   Cell 1990;63:843-9.  DOI  PubMed
               4.       Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575-8.  PubMed
               5.       Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta
                   Neuropathol 2020;139:625-41.  DOI  PubMed  PMC
               6.       Pecoraro A, Arehart E, Gallentine W, et al. Epilepsy in neurofibromatosis type 1. Epilepsy Behav 2017;73:137-41.  DOI  PubMed
               7.       Koczkowska M, Callens T, Gomes A, et al. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1
                   gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med 2019;21:867-76.  DOI  PubMed  PMC
               8.       Quintáns B, Pardo J, Campos B, et al. Neurofibromatosis without neurofibromas: confirmation of a genotype-phenotype correlation
                   and implications for genetic testing. Case Rep Neurol 2011;3:86-90.  DOI  PubMed  PMC
               9.       Upadhyaya M, Huson SM, Davies M, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17
                   of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet
                   2007;80:140-51.  DOI  PubMed  PMC
               10.      Rojnueangnit K, Xie J, Gomes A, et al. High incidence of Noonan syndrome features including short stature and pulmonic stenosis in
                   patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation. Hum Mutat 2015;36:1052-63.  DOI
                   PubMed  PMC
               11.      Muram-Zborovski TM, Vaughn CP, Viskochil DH, Hanson H, Mao R, Stevenson DA. NF1 exon 22 analysis of individuals with the
                   clinical diagnosis of neurofibromatosis type 1. Am J Med Genet A 2010;152A:1973-8.  DOI  PubMed  PMC
               12.      Hsieh HY, Fung HC, Wang CJ, Chin SC, Wu T. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but
                   not to neurofibromatosis bright objects. Seizure 2011;20:606-11.  DOI  PubMed
               13.      Kuroda N, Fujimoto A, Okanishi T, Sato K, Nishimura M, Enoki H. Epilepsy surgery for a patient with neurofibromatosis type 1
                   concomitant with moyamoya syndrome. J Clin Neurosci 2019;61:307-10.  DOI  PubMed
               14.      Griffiths PD, Blaser S, Mukonoweshuro W, Armstrong D, Milo-Mason G, Cheung S. Neurofibromatosis bright objects in children
                   with neurofibromatosis type 1: a proliferative potential? Pediatrics 1999;104:e49.  DOI  PubMed
               15.      Griffith JL, Morris SM, Mahdi J, Goyal MS, Hershey T, Gutmann DH. Increased prevalence of brain tumors classified as T2
                   hyperintensities in neurofibromatosis 1. Neurol Clin Pract 2018;8:283-91.  DOI  PubMed  PMC
               16.      Billiet T, Mädler B, D'Arco F, et al. Characterizing the microstructural basis of “unidentified bright objects" in neurofibromatosis type
                   1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis. Neuroimage Clin 2014;4:649-58.  DOI
                   PubMed  PMC
   5   6   7   8   9   10   11   12   13   14   15